Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.
Also called NCT04970238
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 500 participants
- Sponsor
- Registry
-
NCT04970238
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT04970238. Randomized; double masking; primary purpose prevention. Start 2021-10 (anticipated); primary completion 2023-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction
- Condition
- ST Elevation Myocardial Infarction
- Condition
- Heart Failure
- Intervention (Drug)
- Levosimendan
- Intervention (Other)
- placebo
- Lead sponsor
- Zhijun Sun
Record details
- Record id
cardio:ct-nct04970238- Content hash
7c8812b4a1cba96edb69e12cbee1db29f01127e8332e16ed40d71bf71956d481